Accelerated Approvals Perked Up While US FDA Excelled At Being Average In 2025

 
• By Bridget Silverman
  
While most US FDA performance metrics for novel agents matched the 10-year average, accelerated approvals increased in 2025. (Shutterstock)
In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Market Access

More from In Vivo